Kevan M. Shokat
The chemist whose lab found the hidden pocket in KRAS G12C that made the 'undruggable' target druggable.
Kevan Shokat is a chemical biologist. His 2013 discovery of covalent inhibitors binding the switch-II pocket of KRAS G12C opened the path to sotorasib and adagrasib. Also known for the bump-hole approach to kinase chemical genetics.
Pages like this
not linked directly; found by shared links- PersonFrank McCormick
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
- TrialKrascendo 1
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- RoadmapKRAS roadmap: undruggable → G12C → pan-RAS
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- PairingKRAS G12C inhibitor + anti-EGFR antibody (colorectal)
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.